Literature DB >> 19003592

Mechanisms of minocycline-induced suppression of simian immunodeficiency virus encephalitis: inhibition of apoptosis signal-regulating kinase 1.

Susan C Follstaedt1, Sheila A Barber, M Christine Zink.   

Abstract

Human immunodeficiency virus (HIV) infection of the central nervous system (CNS) can lead to cognitive dysfunction, even in individuals treated with highly active antiretroviral therapy. Using an established simian immunodeficiency virus (SIV)/macaque model of HIV CNS disease, we previously reported that infection shifts the balance of activation of mitogen-activated protein kinase (MAPK) signaling pathways in the brain, resulting in increased activation of the neurodegenerative MAPKs p38 and JNK. Minocycline treatment of SIV-infected macaques reduced the incidence and severity of SIV encephalitis in this model, and suppressed the activation of p38 in the brain. The purpose of this study was to further examine the effects of minocycline on neurodegenerative MAPK signaling. We first demonstrated that minocycline also decreases JNK activation in the brain and levels of the inflammatory mediator nitric oxide (NO). We next used NO to activate these MAPK pathways in vitro, and demonstrated that minocycline suppresses p38 and c-Jun N-terminal kinase (JNK) activation by reducing intracellular levels, and hence, activation of apoptosis signal-regulating kinase 1 (ASK1), a MAPK kinase capable of selectively activating both pathways. We then demonstrated that ASK1 activation in the brain during SIV infection is suppressed by minocycline. By suppressing p38 and JNK activation pathways, which are important for the production of and responses to inflammatory mediators, minocycline may interrupt the vicious cycle of inflammation that both results from, and promotes, virus replication in SIV and HIV CNS disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19003592      PMCID: PMC2627770          DOI: 10.1080/13550280802199898

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  62 in total

1.  Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy.

Authors:  Gregory J Dore; Ann McDonald; Yueming Li; John M Kaldor; Bruce J Brew
Journal:  AIDS       Date:  2003-07-04       Impact factor: 4.177

2.  E2F1 modulates p38 MAPK phosphorylation via transcriptional regulation of ASK1 and Wip1.

Authors:  Tzippi Hershko; Katya Korotayev; Shirley Polager; Doron Ginsberg
Journal:  J Biol Chem       Date:  2006-08-15       Impact factor: 5.157

3.  Apoptosis signal-regulating kinase 1-mediated signaling pathway regulates nitric oxide-induced activator protein-1 activation in human bronchial epithelial cells.

Authors:  Itsuro Jibiki; Shu Hashimoto; Shuichiro Maruoka; Yasuhiro Gon; Atsushi Matsuzawa; Hideki Nishitoh; Hidenori Ichijo; Takashi Horie
Journal:  Am J Respir Crit Care Med       Date:  2003-03-15       Impact factor: 21.405

Review 4.  Pathophysiological roles of ASK1-MAP kinase signaling pathways.

Authors:  Hiroaki Nagai; Takuya Noguchi; Kohsuke Takeda; Hidenori Ichijo
Journal:  J Biochem Mol Biol       Date:  2007-01-31

5.  Involvement of p38 mitogen-activated protein kinase and apoptosis signal-regulating kinase-1 in nitric oxide-induced cell death in PC12 cells.

Authors:  O J Han; K H Joe; S W Kim; H S Lee; N S Kwon; K J Baek; H Y Yun
Journal:  Neurochem Res       Date:  2001-05       Impact factor: 3.996

6.  Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.

Authors:  Valerio Tozzi; Pietro Balestra; Rita Bellagamba; Angela Corpolongo; Maria Flora Salvatori; Ubaldo Visco-Comandini; Chrysoula Vlassi; Marinella Giulianelli; Simonetta Galgani; Andrea Antinori; Pasquale Narciso
Journal:  J Acquir Immune Defic Syndr       Date:  2007-06-01       Impact factor: 3.731

7.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

Authors:  Paul H Gordon; Dan H Moore; Robert G Miller; Julaine M Florence; Joseph L Verheijde; Carolyn Doorish; Joan F Hilton; G Mark Spitalny; Robert B MacArthur; Hiroshi Mitsumoto; Hans E Neville; Kevin Boylan; Tahseen Mozaffar; Jerry M Belsh; John Ravits; Richard S Bedlack; Michael C Graves; Leo F McCluskey; Richard J Barohn; Rup Tandan
Journal:  Lancet Neurol       Date:  2007-11-05       Impact factor: 44.182

8.  Increased peroxynitrite activity in AIDS dementia complex: implications for the neuropathogenesis of HIV-1 infection.

Authors:  L A Boven; L Gomes; C Hery; F Gray; J Verhoef; P Portegies; M Tardieu; H S Nottet
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

9.  Regulation of apoptosis signal-regulating kinase 1 degradation by G alpha13.

Authors:  Mikhail A Kutuzov; Alexandra V Andreeva; Tatyana A Voyno-Yasenetskaya
Journal:  FASEB J       Date:  2007-06-26       Impact factor: 5.191

10.  Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease.

Authors:  M I Bukrinsky; H S Nottet; H Schmidtmayerova; L Dubrovsky; C R Flanagan; M E Mullins; S A Lipton; H E Gendelman
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

View more
  23 in total

Review 1.  Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

Authors:  Uraina S Clark; Ronald A Cohen
Journal:  Curr Opin Investig Drugs       Date:  2010-08

2.  Elevated brain monoamine oxidase activity in SIV- and HIV-associated neurological disease.

Authors:  Kelly A Meulendyke; Ceereena Ubaida-Mohien; Julia L Drewes; Zhaohao Liao; Lucio Gama; Kenneth W Witwer; David R Graham; M Christine Zink
Journal:  J Infect Dis       Date:  2014-03-31       Impact factor: 5.226

Review 3.  Mitogen-activated protein kinase p38 in HIV infection and associated brain injury.

Authors:  Kathryn E Medders; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2011-02-01       Impact factor: 4.147

4.  Minocycline attenuates HIV-1 infection and suppresses chronic immune activation in humanized NOD/LtsZ-scidIL-2Rγ(null) mice.

Authors:  Maneesh Singh; Pratibha Singh; Dolores Vaira; Mathieu Amand; Souad Rahmouni; Michel Moutschen
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

Review 5.  Unraveling the pathogenesis of HIV peripheral neuropathy: insights from a simian immunodeficiency virus macaque model.

Authors:  Lisa M Mangus; Jamie L Dorsey; Victoria A Laast; Matthias Ringkamp; Gigi J Ebenezer; Peter Hauer; Joseph L Mankowski
Journal:  ILAR J       Date:  2014

6.  Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease.

Authors:  Kelly A Meulendyke; Mikhail V Pletnikov; Elizabeth L Engle; Patrick M Tarwater; David R Graham; M Christine Zink
Journal:  J Neuroimmune Pharmacol       Date:  2011-12-27       Impact factor: 4.147

7.  Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS.

Authors:  Eva-Maria Ratai; Jeffrey P Bombardier; Chan-Gyu Joo; Lakshmanan Annamalai; Tricia H Burdo; Jennifer Campbell; Robert Fell; Reza Hakimelahi; Julian He; Patrick Autissier; Margaret R Lentz; Elkan F Halpern; Eliezer Masliah; Kenneth C Williams; Susan V Westmoreland; R Gilberto González
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

Review 8.  Minocycline: far beyond an antibiotic.

Authors:  N Garrido-Mesa; A Zarzuelo; J Gálvez
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 9.  Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding.

Authors:  Wendy Noble; Claire J Garwood; Diane P Hanger
Journal:  Prion       Date:  2009-04-21       Impact factor: 3.931

Review 10.  HIV-related neurocognitive impairment in the HAART era.

Authors:  Jessica Robinson-Papp; Kathryn J Elliott; David M Simpson
Journal:  Curr HIV/AIDS Rep       Date:  2009-08       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.